Healio (11/18, Gramigna) reports, “A blood test may be able to identify individuals at increased risk for developing Alzheimer’s disease [AD] symptoms,” researchers concluded in a study that “incorporates a blood test called PrecivityAD, developed by CN Diagnostics.” To date, “the test has shown 81% accuracy…for prediction of amyloid level on a positron-emission tomography scan among individuals without AD symptoms.” This “blood test is set to be used in the AHEAD Study, a clinical trial seeking to prevent AD symptoms that is enrolling individuals as young as age 55 years.” The findings were presented at the Clinical Trials on Alzheimer’s Disease conference. (SOURCE: APA Headlines)